Abstract
AbstractChildren with autism frequently present with complex mental health diagnoses and psychotropic medications are often a component of comprehensive biopsychosocial treatment plans for these conditions. The purpose of this study is to provide rates and patterns of psychotropic medication use, and predictors thereof, in children and youth with autism enrolled in Medicaid across the US. This study examined national Medicaid claims from 2008 to 2016 of all children and youth with autism ages 0–21 years enrolled in Medicaid. Psychotropic medication use was examined across several child and youth characteristics, including age, co-occurring mental health conditions, sex, and race and ethnicity. About half of children and youth with autism enrolled in Medicaid had at least one psychotropic prescription in a year, a number that decreased slightly across the study period due to decreases in the prescription of antipsychotics. As new medications for autism or co-occurring conditions are developed and deployed, and as the understanding of the characteristics of the population of children with autism evolves, studying rates of medication usage helps to understand utilization patterns and differences in access to quality care.
Funder
Pennsylvania Department of Health
Health Resources and Services Administration
National Institutes of Health
Michael Smith Health Research BC
Canadian Foundation for Innovation
Publisher
Springer Science and Business Media LLC
Subject
Developmental and Educational Psychology
Reference35 articles.
1. Abosi, O., Lopes, S., Schmitz, S., & Fiedorowicz, J. G. (2018). Cardiometabolic effects of psychotropic medications. Hormone Molecular Biology and Clinical Investigation. https://doi.org/10.1515/hmbci-2017-0065
2. Alfageh, B. H., Man, K. K., Besag, F. M., Alhawassi, T. M., Wong, I. C., & Brauer, R. (2020). Psychotropic medication prescribing for neuropsychiatric comorbidities in individuals diagnosed with autism spectrum disorder (ASD) in the UK. Journal of Autism and Developmental Disorders, 50(2), 625–633.
3. Ali, M. M., Sherman, L. J., Lynch, S., Teich, J., & Mutter, R. (2019). Differences in utilization of mental health treatment among children and adolescents with Medicaid or private insurance. Psychiatric Services, 70(4), 329–332.
4. American Academy of Child Adolescent Psychiatry (AACAP). (2015). Recommendations about the use of psychotropic medications for children and adolescents involved in child-serving systems. https://www.aacap.org/App_Themes/AACAP/docs/clinical_practice_center/systems_of_care/AACAP_Psychotropic_Medication_Recommendations_2015_FINAL.pdf
5. Brown, M., Duff, H., Karatzias, T., & Horsburgh, D. (2011). A review of the literature relating to psychological interventions and people with intellectual disabilities: Issues for research, policy, education and clinical practice. Journal of Intellectual Disabilities, 15(1), 31–45.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献